Sanofi-Aventis' Merilog version of the ... Before Merilog, the FDA has given the go-ahead to two biosimilars of Sanofi's basal insulin product Lantus (insulin glargine) – Viatris' Semglee ...
WAGM-TV on MSN3d
Attorney General Aaron M. Frey Announces Settlement Agreement Will Bring $35 Insulin to MainersAttorney General Aaron M. Frey announced a settlement agreement with Sanofi-Aventis U.S. LLC after scrutiny over the ...
Under the settlement, Mainers who are uninsured or have commercial health insurance will be eligible to purchase monthly ...
Frey announced the agreement with Sanofi-Aventis U.S. LLC after scrutiny over the company’s pricing of insulin products. “Insulin is life-sustaining medication and far too many Mainers ...
the U.S. Food and Drug Administration (“FDA”) approved Sanofi-Aventis U.S. LLC’s (“Sanofi”) MERILOG™ (insulin-aspart-szjj), a biosimilar to Novo Nordisk A/S’s (“Novo Nordisk ...
South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...
More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin Lantus, the FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency ...
“Merilog, a rapid-acting human insulin analog ... The FDA granted approval of Merilog to Sanofi (SNY)-Aventis U.S. Published first on TheFly – the ultimate source for real-time, market ...
(RTTNews) - The U.S. Food and Drug Administration announced that Sanofi-Aventis U.S. LLC's Merilog (insulin-aspart-szjj) becomes the first rapid-acting insulin biosimilar product to get its ...
Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback